Abstract Deregulation of apoptosis is a hallmark of human cancer and contributes to therapeutic resistance. Recent advances in cancer genomics have revealed a myriad of alterations in key pathways that directly or indirectly increase tumor cell survival. This review outlines the pathways of apoptosis in mammalian cells, and highlights the common alterations of apoptosis regulators found in colon cancer, the role of apoptosis, and underlying mechanisms in colon cancer treatment and prevention, including recent advances in investigational agents, such as kinase inhibitors, proteasome inhibitors, heat shock protein 90 inhibitors, BH3 mimetics, tumor necrosis factor related apoptosis-inducing ligand, and inhibitor of apoptosis protein antagonists. The topics also include novel concepts as well as opportunities and challenges for drug discovery and combination therapy by exploring cancerspecific genetic defects, and therefore selective induction of apoptosis in cancer cells. Although the emphasis is on colon cancer, the main theme and many of the aspects are applicable to other solid tumors.
Introduction
Apoptosis, also known as programmed cell death, is an evolutionarily conserved cell suicidal process essential for managing stress and maintaining tissue homeostasis in multicellular organisms. It consists of a series of well-ordered biochemical events which are regulated by a network of proteins containing distinctive functional domains. Apoptosis serves as a safeguard mechanism against tumorigenesis. During oncogenic transformation, neoplastic cells become resistant to apoptosis as a result of genetic and epigenetic alterations [1] . Defective apoptosis regulation drives other tumorigenic events, such as extended lifespan, accumulation of further genetic mutations, growth under stress conditions, and tumor angiogenesis and metastasis, and contributes to therapeutic resistance [1] . Colorectal cancer is one of the commonest cancers, with an estimated 140,000 new cases and over 50, 830 deaths in 2013 in the USA, and over 1.2 million new cases and 600,000 deaths worldwide [2] . Research in colon cancer has provided fundamental insights into cancer biology, treatment, and prevention. This review provides an overview of the current understanding of the apoptotic pathways, and their deregulation in colon cancer. Discussions will cover advances in selective induction of apoptosis in neoplastic cells, and will explore novel concepts such as cross talk among cell death and cell survival pathways and synthetic lethality for cancer drug development and combinations.
Apoptotic Pathways
Apoptosis is initiated and executed by a series of well-ordered biochemical events and is regulated by complex signaling networks. There are two major apoptotic pathways, termed the extrinsic and intrinsic pathways (Fig. 1) , which are responsible for processing stress signals and executing cell demise in mammalian cells. Although distinctively regulated, these two pathways frequently talk with each other.
The extrinsic apoptotic pathway is engaged on binding of proapoptotic ligands to cell-surface death receptors of the tumor necrosis factor (TNF) receptor family. All death receptors contain a cysteine-rich extracellular domain for ligand binding, and an intracellular death domain for transmitting signals through the recruitment of effectors. Proapoptotic ligands belong to the extended cytokine TNF superfamily, and are either present on the cell surface or secreted into the extracellular space [3] . On binding of proapoptotic ligands to their respective receptors, each receptor can independently form a death-inducing signaling complex (DISC) by recruiting the adapter protein Fas-associated protein with death domain (FADD), along with procaspase 8 and procaspase 10 ( Fig. 1) [3] . FADD recruitment and DISC formation lead to processing and activation of caspase 8 and caspase 10, and their release into the cytoplasm triggers subsequent activation of effector caspases to execute apoptosis (Fig. 1) [3] . FLICE-like inhibitory protein (FLIP) is a caspase-like protein lacking the catalytic function, which suppresses caspase 8 activation [4] .
The intrinsic apoptotic pathway is triggered by stress such as DNA damage, deregulated oncogenes, or growth factor deprivation, and is largely regulated by the Bcl-2 family of proteins and mitochondria [5] (Fig. 1) . For example, DNA damage activates the tumor suppressor p53, which transmits death signals by inducing the expression of BH3-only proteins to allow the activation of Bax and Bak. This in turn leads to mitochondrial outer membrane permeabilization [6] , and release of several mitochondrial apoptogenic proteins, including cytochrome c , SMAC/Diablo, Omi/HtrA2, apoptosisinducing factor, and endonuclease G. Cytochrome c promotes the assembly of the apoptosome and subsequent activation of Fig. 1 Coaxing cancer cells into apoptosis. Apoptosis in mammalian cells is mediated through the intrinsic and extrinsic pathways. The intrinsic pathway is predominantly regulated by the Bcl-2 family and mitochondria. The extrinsic pathway is engaged on binding of proapoptotic ligands, such as tumor necrosis factor related apoptosis-inducing ligand (TRAIL) or Fas to their respective death receptors on the cell surface. Apoptosis initiation is regulated by transcription as well as the cross talk of two apoptotic pathways via Bid. Apoptosis is activated by anticancer agents, such as radiation, chemotherapy, kinase inhibitors, BH3 or SMAC mimetics, and chemopreventive agents acting on both pathways and various players, to trigger a caspase activation cascade. Inhibition of apoptosis or certain caspases such as caspase 8 can lead to increased autophagy or necrosis, providing additional targets for drug development. Antiapoptotic proteins are in green and proapoptotic proteins are in red. Cyto c cytochrome c, DISC death-inducing signaling complex, FasL Fas ligand, IAP inhibitor of apoptosis protein caspase 9, which is facilitated by SMAC/Diablo and HtrA2/ Omi, which antagonize members of the inhibitors of apoptosis protein (IAP) family. Apoptosis-inducing factor and endonuclease G promote DNA degradation [7, 8] . In cells with low levels of DISC, caspase-8-dependent cleavage of the BH3-only protein Bid generates truncated Bid to amplify apoptotic signaling via Bax/Bak and the mitochondria (Fig. 1) [5] .
Deregulation of Apoptosis in Cancer
Maintenance of tumor phenotypes is highly dependent on apoptosis suppression by certain prosurvival proteins, to evade the fate of cell killing imposed by "oncogenic stress" during neoplastic transformation. Many key pathways controlling apoptosis and cell survival are therefore commonly altered in cancer [1, 9••] . Genetic alterations are generally found in the more proximal components rather than the core apoptotic machinery or downstream effectors, suggesting a strong selective pressure during carcinogenesis to disable nodal points critical for apoptosis initiation, such as p53. Data from genetically manipulated mice also support apoptosis as an important mechanism for tumor suppression in the intestinal tract.
Alterations in the Proximal Regulators

Transcription Factors
Apoptosis initiation is heavily regulated at the level of gene expression. The best studied and most highly relevant to cancer are the transcription factors p53 and NF-κB. Transcription factors p53 is essential for preventing inappropriate cell proliferation and for maintaining genome integrity following genotoxic stress, and is mutated or inactivated in over half of human cancers [6, 9••] . Tumor-derived p53 mutants are defective in transcription and apoptosis induction [6, 10] . NF-κB plays a key role in cancer and inflammation, and its overexpression or activation is linked to chemoresistance [11] . On stimulation by proinflammatory cytokines, cytoplasmic NF-κB is released from inhibitor of κB (IκB), and translocates to the nucleus to regulate gene expression. Wellknown antiapoptotic targets of NF-κB include Bcl-2-like proteins, IAPs, and cellular FLIP (c-FLIP) [11] .
Protein Kinases
Kinases are key regulators of normal cell physiology and play critical roles in the development and progression of human cancer. Aberrant activation of receptor tyrosine kinases (RTKs) and non-RTKs ultimately contributes to tumor initiation and maintenance of tumor phenotypes such as cell survival, proliferation, migration, and tumor angiogenesis [1, 9••], and confers resistance to cancer therapy [12••] . Aberrant activation of RTKs, such as epidermal growth factor receptor (EGFR; ErbB1), hepatocyte growth factor receptor MET, plateletderived growth factor receptor ,and vascular endothelial growth factor (VEGF) receptor, engages intracellular kinase cascades such as Ras/B-Raf/extracellular-signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase (PI3K)/Akt/ mammalian target of rapamycin (mTOR). Activation of these non-RTKs is also caused by gene mutations and amplifications in colon cancer [9••] .
Alterations in the Bcl-2 Family of Proteins Antiapoptotic Bcl-2 family members are frequently overexpressed in solid tumors, whereas proapoptotic Bcl-2 family members are downregulated or mutated [5] . In rare cases, homozygous deletions or inactivating mutations of BAX are found, particularly in DNA mismatch repair deficient colorectal tumors [13] . The activities or levels of proapoptotic proteins are often suppressed by oncogenic kinases. For example, PI3K/Akt or ERK inactivates Bad by phosphorylation [14] , and suppresses PUMA induction [15, 16, 17] . PUMA ablation in mice leads to decreased apoptosis and increased tumor burden and invasiveness in the gastrointestinal tract [18••] .
Alterations in the Extrinsic Pathway and Other Apoptotic Components
In contrast to the deregulation in the upstream regulators or Bcl-2 family, direct impairments of the extrinsic pathway and downstream apoptotic effectors by genetic alterations are generally rare in human cancer, whereas altered expression is common [3, 19, 20] . Overexpression of c-FLIP [4] , particularly c-FLIP long form, functions as a survival factor in colon cancer [21] . Elevated X-linked IAP [22] or cellular IAP2 [23] expression or reduced SMAC expression [24] is correlated with disease progression, metastasis, or poor survival in colon cancer patients. The levels of SMAC inversely correlated with the levels of cellular IAP2 and tumor grade, and its ablation accelerates cancer progression in mice [25] . Lost expression or deletion of DR4 and DR5, overexpression of decoy receptor DcR3 or DcR1 [3] , and caspase 8 (CASP8 ) polymorphisms or deletion have been reported in other cancers, however not in colon cancer.
Apoptosis Induction in Colon Cancer Treatment and Resistance Mechanisms
Induction of apoptosis is a major cytotoxic mechanism of anticancer therapies, including radiation therapy, chemotherapy, and targeted therapies (Fig. 1) [3, 5, 12••, 26] . Targeted therapies are expected to have improved specificity and reduced toxicity, and ultimately help move oncology practice toward personalized treatment [27] . Cancer cells can develop various mechanisms to evade apoptosis. Deficiency in p53, Bax, PUMA, or caspase activation can cause resistance to radiation therapy and chemotherapy, whereas overexpression of antiapoptotic proteins such as Bcl-X L , c-FLIP, and IAPs is frequently associated with therapeutic resistance. Mutations in kinases and their cross talk modulate therapeutic responses to targeted therapies in patients.
Radiation and Chemotherapy
Radiation and most conventional chemotherapeutic agents induce DNA damage. Following DNA damage, p53 undergoes extensive posttranslational modifications, including phosphorylation and acetylation, which stabilize p53 and enhance its transcriptional activities [6] . DNA-damageinduced apoptosis is mediated by p53 primarily via the intrinsic pathway, through the BH3-only protein PUMA, and Noxa to a lesser extent, in various cancer cells and normal tissues [28] [29] [30] . In addition, DR5 and PIDDosome/caspase 2 [31] are implicated in apoptosis induced by 5-fluorouracil in colon cancer cells, which is partially dependent on p53 [32] . Under some conditions, cytoplasmic p53 inactivates Bcl-2 like proteins at the mitochondria [33] , although the significance and mechanisms are not well understood. Moreover, genotoxic stress can activate p53 family proteins such as p73 and p63, which share many proapoptotic targets with p53 [34] .
On the other hand, p53 plays a key role in the pathologic apoptosis of tissue stem cells and acute side effects induced by radiation and chemotherapy in the bone marrow and gastrointestinal tract [29, 30, 35] . Given the prevalence of p53 alterations in cancer [6] , it is tempting to speculate that enhancement of p53-independent induction of apoptosis genes in cancer cells and/or suppression of p53-dependent apoptosis in normal tissues can be exploited to widen the therapeutic index.
Targeted Therapies
Anti-EGFR Therapy EGFR-targeting agents, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, have been used to treat different tumor types. EGFR TKIs are particularly useful in treating a subset of lung cancers harboring oncogenic EGFR mutations. Cetuximab and panitumumab, two anti-EGFR monoclonal antibodies, are effective in combination with chemotherapy or as single agents for the treatment of metastatic colon cancer. However, mutations in KRAS, BRAF, and PIK3CA are associated with resistance to anti-EGFR therapies [27] . Apoptosis is induced by EGFR TKIs in a variety of tumor cells through the intrinsic pathway by modulating the BH3-only proteins, such as Bim and PUMA [17, 36, 37] . Clinical response to EGFR TKIs is correlated with induction of apoptosis in tumor cells, and defective apoptosis regulation contributes to resistance of EGFR-targeted therapy [38] .
Anti-VEGF Therapy
Bevacizumab (Avastin), a recombinant humanized monoclonal antibody against VEGF, is used in combination with conventional chemotherapy for treating metastatic colorectal cancer. Several studies suggest induction of apoptosis in tumor cells contributes to the therapeutic effect of bevacizumab. In xenograft models, antitumor effects of bevacizumab are correlated with hypoxia-induced apoptosis [39] . Combined use of bevacizumab and irinotecan (CPT-11) strongly induced apoptosis and improved therapeutic efficacy against lung metastasis from colon cancer [40] . In bevacizumab-treated metastatic colon cancer patients, the serum level of TNF-related apoptosis-inducing ligand (TRAIL) was found to be elevated, which correlated with patient survival [41, 42] .
Sorafenib/Regorafinib
Sorafenib (Nexavar) is the first FDA-approved oral multikinase-inhibitor drug that targets the Ras/Raf/MEK/ERK pathway. Sorafenib inhibits c-Raf, B-Raf, platelet-derived growth factor receptor, and VEGF receptors, and has been used for the treatment of advanced kidney and liver tumors [43, 44] . Regorafenib (BAY 73-4506, Stivarga), a sorafenib analog with an extra fluoro group, has recently been approved for the treatment of metastatic colorectal cancer and advanced gastrointestinal stromal tumors that are resistant to other therapies. The anticancer effects of sorafenib/regorafenib are thought to be mediated by apoptosis induction, in addition to their antiproliferative and antiangiogenic effects, and are enhanced when they are combined with cytotoxic agents [43, 44] . Sorafenib-induced apoptosis is associated with downregulation of Mcl-1 and inhibition of eukaryotic translation initiation factor 4E phosphorylation [45, 46] , as well as the induction of PUMA through NF-κB in colon cancer cells [47•] , and Bim in leukemia cells [48] .
Other Targeted Therapies and Investigational Agents
Numerous investigational drugs are in the various stages of clinical development for treatment of colon cancer and have been found to stimulate apoptosis. Vemurafenib (PLX4032), a selective inhibitor of B-Raf V600E mutant, has shown significant activity in B-Raf mutant (V600E) melanomas, but only very limited efficacy in colon cancers with the same mutation. The intrinsic and acquired resistance to B-Raf inhibitors involves feedback activation of the PI3K/Akt, mTOR, or EGFR pathway, and can be overcome by the inhibitors of these pathways via apoptosis induction [49, 50, 51•] . Nonselective kinase inhibitors such as UCN-01 [15] and sunitinib [52] induced PUMA-dependent, but p53-independent apoptosis in colon cancer cells. MET/anaplastic lymphoma kinase inhibitors such as crizotinib induced both p53-dependent and p53-independent apoptosis, and synergized with EGFR TKI or Raf inhibitors to induce PUMA and apoptosis [53•] . Additional inhibitors against the Raf/MEK/ERK and PI3K/phosphatase and tensin homolog/Akt/mTOR pathways are in development [12••] . Therefore, systematic approaches are needed to determine optimal use of these agents in the correct patients (see "Exploring Synthetic Lethality in Cancer Therapy and Prevention").
In addition to kinase inhibitors, several other classes of agents also induce apoptosis in cancer cells. The proteasome inhibitor bortezomib (Velcade), approved for treating multiple myeloma, triggers apoptosis alone or in combination with chemotherapy by modulating the Bcl-2 family and NF-κB pathway [54, 55] . Heat shock protein 90 (Hsp90) is one of the most abundant molecular chaperones in eukaryotes and is expressed at much higher levels in tumor cells. Currently, over 17 Hsp90 inhibitors have entered clinical trials. These agents are found to induce apoptosis and overcome resistance to BRaf or PI3K/Akt/mTOR inhibitors in preclinical models [56] . Several proapoptotic mechanisms, likely to be cell-type specific, have been suggested, including downregulation of Hsp90 client oncoproteins such as mutant p53, c-Raf, Akt, NF-κB, and Her2 [56] , or activation of wild-type p53 [57] .
Apoptosis and Cancer Prevention
Cancer prevention is expected to have a great impact on cancer mortality. Chemoprevention is a promising anticancer strategy, referring to the use of pharmacologic agents or natural products to intervene early in the process of tumor development [58] . Epidemiological studies, clinical trials, and animal studies have shown that the widely used nonsteroidal anti-inflammatory drugs (NSAIDs) prevent intestinal cancer in humans and mice, particularly in high-risk individuals who carry germ-line APC mutations [9••, 59] . NSAIDs are also useful in preventing other types of cancer, and as an adjuvant therapy [60] .
Several anticancer mechanisms of NSAIDs and other cancer preventive agents have been described, such as inhibition of cyclooxygenases [60] and induction of apoptosis [61] . Mechanistic studies demonstrated that Bax and SMAC/ Diablo mediate the anticancer effects of NSAIDs by promoting apoptotic cell death [62] [63] [64] 65 ••], likely by cross talk between the death receptor and the mitochondrial apoptotic pathways (Fig. 1) . Manipulating apoptosis or using a combination of different classes of chemopreventive agents can enhance the effectiveness of NSAIDs [64] , and reduce toxicity by lowering the doses [66] .
One of the earliest events in colorectal tumorigenesis is genetic alterations in the APC tumor suppressor pathway leading to aberrant Wnt signaling and subsequent nuclear translocation of β-catenin, and activation of oncogenes such as c-MYC and CCND1 [9••] , and likely targeting the intestinal stem cells [67] . NSAID treatment selectively induced apoptosis to remove intestinal stem cells with aberrant Wnt signaling [65••] . Adenoma samples from patients taking NSAIDs were also found to have enhanced apoptosis induction in cells with expression of stem cell markers and aberrant Wnt signaling [65••] , suggesting that NSAIDs eliminate stem cells that have acquired oncogenic mutations to prevent intestinal tumorigenesis.
Apoptosis Cross Talk with Other Death and Survival Mechanisms
Although apoptosis is a major mode of cell death in response to anticancer agents, several alternative cell death pathways have recently been identified, in particular autophagy and programmed necrosis (Fig. 1) . These pathways are engaged in response to specific stimuli, upon a restricted condition, or within a time window during cell death. The interplay among different cell death pathways can sometimes play a critical role in determining therapeutic response and development of drug resistance, and is partially mediated by the competition of shared regulators or adaptors.
Autophagy
Autophagy is a self-eating process of cells that has recently emerged as an important stress response and cell death mechanism, and is regulated by a group of evolutionarily conserved autophagy-related genes (ATGs) [68] . It is characterized by the formation of double-membrane autophagosomes, which fuse with lysosomes to promote degradation of damaged organelles or cytosolic materials [69] . Autophagy can either promote or inhibit cell death, and is often cytoprotective in cancer cells [70] . Inhibition of autophagy sensitizes cancer cells to chemotherapy, and autophagy inhibitors such as hydroxychloroquine are being tested in a number of clinical trials [71] . Autophagy interconnects with apoptosis in a number of ways [72] . Bcl-2-interacting protein 1 (beclin 1), a key regulator of autophagy, contains a BH3 domain that can interact with Bcl-2 and Bcl-X L [73] , which inhibit autophagy [74] . Several ATG proteins, including beclin 1, ATG5, and ATG4D, can be cleaved by caspases and other proteases during apoptosis [75, 76] . Specific ablation of caspase-8-mediated beclin 1 cleavage restored autophagy in apoptotic cells, and enhanced cancer cell survival and therapeutic resistance [77•] .
Necrosis
Necrosis is characterized by ATP depletion, swelling of organelles, and spilling of cellular contents, and some forms of necrosis are found to be regulated. In the absence of cellular IAPs, TNF-α stimulates the formation of a secondary cytoplasmic complex similar to DISC, leading to rapid activation of caspase 8 and subsequently apoptosis [64, 78, 79] , which is largely blocked by caspase inhibitors in most cell types. In some cells, caspase inhibitors or genetic ablation of caspase 8 can switch the apoptotic response to necrosis mediated by receptor-interacting protein kinase 1 or receptor-interacting protein kinase 3 [80, 81••] . Necrosis often leads to inflammation, the significance of which in cancer biology and therapy and the underlying mechanisms of which remain to be elucidated.
Apoptosis-Targeted Agents in Development for Cancer Therapy
Several strategies have been devised to induce killing of cells by manipulating apoptotic regulators directly. Smallmolecule or antisense inhibitors of prosurvival Bcl-2 family members or the IAP antagonists promote apoptosis by inhibiting antiapoptotic signaling within the cells. The protein-based agents trigger apoptosis from the cell surface by stimulating death receptors. Most of these agents have limited toxicity toward cancer cells as single agents, but potently synergize with radiation or conventional chemotherapy in preclinical studies.
Bcl-2 Antagonists
Compared with peptidyl and small-molecule BH3 mimetics, antisense oligonucleotides against various antiapoptotic Bcl-2 family members have limited success. Only the Bcl-2 antisense oligonucleotide oblimersen advanced to clinic trials. Owing to their more desirable pharmacological properties, extensive preclinical studies have been conducted on various BH3 mimetics, including HA14-1, antimycin A and analogs, BH3 inhibitors, gossypol and analogs, and GX015-070 [82] . The most promising BH3 mimetic is ABT-737, which potently inhibits Bcl-2 and Bcl-X L , but not MCL-1, to induce Bax/Bak-dependent apoptosis [83, 84] . As a single agent, ABT-737 and most BH3 mimetics had limited efficacy in selective types of cancer cells [83] , but they exhibited striking synergy with a variety of anticancer agents in colon cancers [15, 47•, 52] . ABT-263, an orally available derivative of ABT-737, is currently being evaluated in clinical trials [85] .
Death Receptor Ligands or Agonists
Recombinant human TRAILhas shown promise in both preclinical and clinical studies, suggesting the importance of DR4 and DR5 in killing cancer cells [19] . Deficiency in CASP8 [3, 19] , BAX [62] , or DIABLO [63] , but not p53 [3] is associated with TRAIL resistance. Mapatumumab (HGS-ETR1) is the only human agonistic antibody for DR4 that has advanced to clinical trials, showing some efficacy in combination regimens [3] . The clinical outlook of Fas ligand or TNF-α is limited because of severe side effects associated with inflammation [3] .
IAP Antagonists
SMAC/Diablo and Omi/HtrA2 are endogenous IAP inhibitors, also called IAP antagonists, and relieve the antiapoptotic activities of several IAPs [20] . The synthesis of SMAC mimetics that resemble either monomeric or dimeric N-terminal IAP-binding AVPI peptide of SMAC is a great example of structure-based drug design [20, 86] . Both monovalent and divalent SMAC mimetics are currently in phase I and phase II trials [20, 86] . As single agents, SMAC mimetics exert little or no toxicity in nonmalignant human cells, and only induce apoptosis in a limited number of cancer cell lines via TNF-α production [79] . SMAC mimetics or forced SMAC expression sensitizes cancer cells to apoptosis induced by various classes of anticancer agents, including chemotherapeutics, radiation, death receptor agonists, and kinase inhibitors, by enhancing caspase activation [64] , release of endogenous SMAC [87] , and degradation of cellular IAP1/2 [20] .
Exploring Synthetic Lethality in Cancer Therapy and Prevention
The concept of synthetic lethality borrowed from yeast genetics has recently been used to discover new anticancer agents or targets based on cancer-specific genetic changes [88] . Use of isogenic cells combined with small interfering RNA or small-molecule library screens has identified several synthetic lethal interactions in colon cancer cells. For example, KRAS mutation is synthetic lethal with the inhibition of the mitotic machinery, the proteasome [89] , STK33 kinase [90] , TAK1 [91] , transcription factor GATA2, DNA replication factor CDC6 [92] , and MEK/Bcl-X L [93•] . Overexpression of cMyc is synthetic lethal with aurora B kinase inhibition [94] . Interestingly, TRAIL is synthetic lethal with either Ras or cMyc [95, 96] . Cell killing in these settings is likely mediated through apoptosis. Synthetic lethal interactions with DNA repair deficiencies are of therapeutic interest, such as the poly(ADP) ribose inhibitors and BRCA1/BRCA2 deficiency in a subset of ovarian or breast cancer [97] , and mismatch repair protein MSH2 and DNA polymerase β and mismatch repair protein MLH1 and polymerase γ in colon cancer cells [98, 99] .
The discovery of novel synthetic lethal interactions has important implications in cancer treatment and prevention. Ras mutant tumors account for 40-50 % of colon cancer, whereas c-MYC overexpression is an early and nearly universal event in colon cancer resulting from the loss of the tumor suppressor APC [9••] . The advantages of this approach include reduction of side effects by using lower doses of conventional therapies, and increase in therapeutic efficacy through rationale combinations [100•] . It is likely that cancer-driver mutations will play a key role in the understanding of gene-gene and gene-drug interactions and therapeutic resistance as discussed before.
Conclusion
Apoptosis in mammalian cells is regulated by two major pathways. Integration of apoptotic signals is achieved through the cross talk among many upstream signals and downstream effectors, influencing the decision between life and death. Alterations in the apoptotic pathways are complex, with genetic alterations found mostly in the upstream regulatory proteins, providing many potential targets for drug development. One of the main goals of cancer research is to develop safer and more effective therapies, which might capitalize on a better understanding of the cancer genome as well as cancerspecific synthetic lethal interactions. A great challenge ahead is to understand in biochemical detail the integration modules and nodes of the apoptotic pathways to help drug development and delineation of therapeutic resistance mechanisms. Another big challenge is to identify biomarkers that can help stratify patients for treatments and follow-up. Such efforts are expected to ultimately lead to personalized medicine. 
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